Metabolic syndrome (does it have a common denominator?).
The insufficient or inappropriate supply of PUFA OMEGA-3 (esp. docosahexaenoic and eicosa pentaenoic acid DHA and EPA) can be suggested to be a common factor of the four metabolic syndrome's clinical manifestations. DHA can be considered as one of the most important element of the membrane. The protective and beneficial effects of DHA (and EPA) result from the dynamic qualities of its molecular structure as well as from its recently detected effects on the genetic expression of several cytokines, enzymes etc. Dietary supplementation of DHA improves all clinical symptoms and laboratory biochemical markers of the metabolic syndrome. Together with that, depletion of DHA was found in diabetes and in several cardiovascular diseases. Also the developmental aspect and approach supports our view. With high probability DHA represents one of the connecting components of the development of metabolic syndrome's clinical manifestations. Metabolic syndrome could be therefore interpreted as an insufficient function of the cellular membrane.
Mourek
J
J
Charles University in Prague, First Faculty of Medicine, Institute of Physiology, Prague, Czech Republic. jana.miskova@lf1.cuni.cz
D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000378:metabolism; D015118:Eicosapentaenoic Acid / Q000378:metabolism / Q000627:therapeutic use; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D024821:Metabolic Syndrome / Q000378:metabolism / Q000628:therapy*
D015525:Fatty Acids, Omega-3; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid